Home › Chembio Inks Commercialization Deal for Dengue, Zika, Chikungunya Tests

Chembio Inks Commercialization Deal for Dengue, Zika, Chikungunya Tests

May 24, 2018

NEW YORK (360Dx) – Chembio Diagnostics announced today that it has signed an agreement to commercialize its point-of-care tests for Dengue, Zika, and Chikungunya infection in Brazil with Bio-Manguinhos.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS Approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

What's Popular?

In Infectious Disease

  1. Systaaq HBV Assay Receives CE Mark

  2. BioMérieux Culture Bottles Cleared for Platelet Testing With BACT/ALERT Virtuo System

  3. Mobidiag, Autobio Diagnostics to Form Joint Venture in China

  4. Ebola Point-of-Care Test Developed by BD as Proof of Concept for SERS Technology

    Premium

  5. Curetis to Cut 30 Percent of Workforce as Part of Strategic Restructuring

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.